In a clinical trial pitting brodalumab, a new biologic drug for psoriasis, against Stelara (ustekinumab), more patients on brodalumab had completely clear skin after three months, according to a statement released earlier this week from Amgen and AstraZeneca, the makers of brodalumab.

Patients involved in the Phase III study were randomly assigned to take Stelara, a placebo, or 210 milligram (mg) or 140 mg doses of brodalumab, according to the statement, which reported results from the first three months of the study.

READ FULL ARTICLE Curated publisher From